What Does Competitor’s Failure Mean to Alnylam Pharmaceuticals?

According to the announcement on Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) acoramidis, the competitor of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), failed to significantly differentiate from placebo on 6MWD at 12 months in its Phase 3 trial in ATTR cardiomyopathy, the primary endpoint (p=0.76).

Despite this competitor disappointment, Alnylam Pharmaceuticals’ shares are weak, the possible reason of which can be the concerns that the unexpectedly strong performance seen in ATTRibute-CM's placebo group could similarly manifest in Apollo-B.

Analysts at Oppenheimer mentioned that they do not share the market's newfound skepticism and suggest buying the stock on weakness.
Alnylam Pharmaceuticals, Inc. View
Symbol Price %chg
207940.KS 848000 1.53
068270.KS 193200 2.74
196170.KQ 264000 -2.84
028300.KQ 81300 -2.58
ALNY Ratings Summary
ALNY Quant Ranking
Related Analysis